These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24149832)

  • 1. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization.
    Odisio BC; Galastri F; Avritscher R; Afonso BB; Segatelli V; Felga GE; Salvalaggio PR; Ensor J; Wallace MJ; Nasser F
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1018-26. PubMed ID: 24149832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
    Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
    Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
    Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
    Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study.
    Pauwels X; Azahaf M; Lassailly G; Sergent G; Buob D; Truant S; Boleslawski E; Louvet A; Gnemmi V; Canva V; Mathurin P; Pruvot FR; Leteurtre E; Ernst O; Dharancy S
    Cardiovasc Intervent Radiol; 2015 Jun; 38(3):685-92. PubMed ID: 25342136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
    Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
    Huo YR; Xiang H; Chan MV; Chan C
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.
    Kim S; Mannelli L; Hajdu CH; Babb JS; Clark TW; Hecht EM; Taouli B
    J Magn Reson Imaging; 2010 Feb; 31(2):348-55. PubMed ID: 20099348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
    Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
    Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.